Skip to main content

Selective Antigen Specific dTβRII-expressing T cells

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

  • RegistryNCT07172958
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRelapsed/Refractory Embryonal Tumors
  • SponsorChildren's National Research Institute
How SABRE worksNCT071729581 min

What the film says

Read the transcript

This trial is for children and young adults, ages 1 to 23, with relapsed or refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma or Wilms tumor.

The idea: give two kinds of engineered T cells together. One carries a B7-H3 receptor, and the other targets a tumor protein called PRAME. The cells are made from each patient's own blood, collected by apheresis. Patients first receive lymphodepleting chemotherapy.

This phase 1 study plans 18 participants and tests safety. At Children's National in Washington, D.C., Holly Meany and Amy Hont lead it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07172958

    Ages 1 to 23, relapsed or refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma or Wilms tumor; Two kinds of engineered T cells: B7-H3 CAR T cells and PRAME-targeting T cells; Lymphodepleting chemotherapy first; Phase 1; 18 participants; safety (+2 more lines)

The drug

What is being tested.

Selective Antigen Specific dTβRII-expressing T cells combined with B7-H3 CAR T cells

This protocol is designed as a phase I dose-escalation study. Procurement phase: During the procurement phase of this protocol, upon SABRE Procurement Consent and procurement eligibility confirmation, participants will undergo a non-mobilized apheresis for collection of mononuclear cells to be used for the CAR-TA T cell product manufacturing.

Treatment phase: Once the CAR-TA T cell products are released and patients are confirmed eligible for CAR-TA T cell product infusion, participants will undergo protocol therapy at participating site(s), consisting of a standard lymphodepleting chemotherapy preparative regimen with fludarabine and cyclophosphamide, followed by intravenous infusion of the combined CAR-TA T cell product.

The study

How the trial runs.

This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma and Wilms tumor.

Patients will be enrolled to one of three planned dose levels with B7-H3 CAR T cell dose determined based on the percentage of B7-H3 transduced cells (B7-H3+ population of cells), and dTBRII-transduced PRAME TA-specific T cell dose based on the total cell population. Both doses will be based on the recipient's body weight and combined in a 1:1 ratio. The safety of the CAR-TA T cell product will be evaluated and the maximum tolerated dose (MTD) will be determined.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Diagnosis of relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, or Wilms tumor
  • Refractory disease, residual detectable disease or relapsed disease following available standard of care therapies with known clinical benefit for their specific tumor type, or unable to receive such therapies due to unacceptable toxicity or contraindication
  • Measurable or evaluable disease by imaging, as determined following most recent therapy
  • Age ≥ 1 year and < 24 years
  • No systemic steroid exposure within 1 week of procurement

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.